Arrowhead Pharmaceuticals (NASDAQ:ARWR) Sets New 52-Week Low – Time to Sell?

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)’s stock price reached a new 52-week low during trading on Tuesday . The stock traded as low as $12.14 and last traded at $12.74, with a volume of 2848318 shares trading hands. The stock had previously closed at $13.82.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on ARWR. Chardan Capital reissued a “buy” rating and issued a $60.00 price target on shares of Arrowhead Pharmaceuticals in a report on Tuesday, February 11th. HC Wainwright reiterated a “buy” rating and issued a $80.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, February 12th. Royal Bank of Canada reissued an “outperform” rating and set a $42.00 price target on shares of Arrowhead Pharmaceuticals in a report on Tuesday, February 11th. StockNews.com upgraded shares of Arrowhead Pharmaceuticals to a “sell” rating in a research report on Friday, December 20th. Finally, B. Riley reissued a “buy” rating and set a $38.00 target price (down from $51.00) on shares of Arrowhead Pharmaceuticals in a research note on Friday, February 14th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, Arrowhead Pharmaceuticals has a consensus rating of “Hold” and a consensus target price of $41.44.

Arrowhead Pharmaceuticals Price Performance

The business’s 50-day simple moving average is $17.70 and its 200 day simple moving average is $19.43. The company has a market capitalization of $1.74 billion, a P/E ratio of -2.45 and a beta of 0.92. The company has a current ratio of 6.09, a quick ratio of 6.09 and a debt-to-equity ratio of 7.27.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its earnings results on Monday, February 10th. The biotechnology company reported ($1.39) EPS for the quarter, missing the consensus estimate of ($0.42) by ($0.97). As a group, sell-side analysts anticipate that Arrowhead Pharmaceuticals, Inc. will post -2.42 EPS for the current year.

Insider Transactions at Arrowhead Pharmaceuticals

In other news, CEO Christopher Richard Anzalone sold 133,333 shares of Arrowhead Pharmaceuticals stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $17.02, for a total value of $2,269,327.66. Following the transaction, the chief executive officer now owns 3,773,802 shares of the company’s stock, valued at $64,230,110.04. The trade was a 3.41 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO Kenneth Allen Myszkowski sold 27,167 shares of the stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $19.83, for a total transaction of $538,721.61. Following the sale, the chief financial officer now directly owns 473,433 shares of the company’s stock, valued at approximately $9,388,176.39. This represents a 5.43 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 274,797 shares of company stock valued at $4,830,279. Corporate insiders own 4.30% of the company’s stock.

Hedge Funds Weigh In On Arrowhead Pharmaceuticals

Hedge funds have recently modified their holdings of the stock. World Investment Advisors LLC boosted its position in shares of Arrowhead Pharmaceuticals by 3.8% in the 3rd quarter. World Investment Advisors LLC now owns 19,132 shares of the biotechnology company’s stock valued at $371,000 after purchasing an additional 700 shares during the period. Xponance Inc. boosted its holdings in shares of Arrowhead Pharmaceuticals by 4.5% in the fourth quarter. Xponance Inc. now owns 17,400 shares of the biotechnology company’s stock worth $327,000 after buying an additional 744 shares during the period. Summit Investment Advisors Inc. increased its position in shares of Arrowhead Pharmaceuticals by 2.2% in the fourth quarter. Summit Investment Advisors Inc. now owns 37,994 shares of the biotechnology company’s stock worth $714,000 after acquiring an additional 803 shares in the last quarter. Wellington Management Group LLP raised its holdings in shares of Arrowhead Pharmaceuticals by 1.5% during the third quarter. Wellington Management Group LLP now owns 61,904 shares of the biotechnology company’s stock valued at $1,199,000 after acquiring an additional 886 shares during the period. Finally, ADAR1 Capital Management LLC lifted its position in shares of Arrowhead Pharmaceuticals by 10.2% in the 4th quarter. ADAR1 Capital Management LLC now owns 12,900 shares of the biotechnology company’s stock valued at $243,000 after acquiring an additional 1,195 shares in the last quarter. 62.61% of the stock is currently owned by institutional investors and hedge funds.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.